1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. DARE BIOSCIENCE INC
Dare Bioscience Inc
XNAS: DARE
Download real time
0.770.00(0.00%)
79.63% Fall from 52W High
68,970
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Dare Bioscience Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Dare Bioscience Inc share price target, revenues, EPS, net income and more

Dare Bioscience Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Dare Bioscience Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 985.9% YoY.

  • POSITIVE

    Quarterly Net Profit Dare Bioscience Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of 25.7% YoY.

Dare Bioscience Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0.20.21-00-0.10001.81
Cost Of Rev.
0.30.20.3-0---
Gross Profit
-0.1-0.10.7-00-00---
⌄
2.82.92.23.73.84.65.34.77.4679.49
Operating Profit
-3-3-1.5-3.7-3.8-4.6-5.4-4.7-7.4-6-5.2-8.4-9
⌄
-------------
Profit Before Tax
-3-3-1.4-3.6-4-4.4-5.5-4.712.9-6.8-5.1-8.3-8.8
Tax
-------------
⌄
-3-3-1.4-3.6-4-4.4-5.5-4.712.9-6.8-5.1-8.3-8.8
Diluted NI Avail to Com Stockholders Ann.
-3-3-1.4-3.6-4-4.4-5.5-4.712.9-6.8-5.1-8.3-8.8
Basic EPS
-0.2-0.2-0-0.3-0.5-0.5-0.7-0.61.5-0.8-0.7-1.1-1.2
Diluted EPS After ExtraOrdinary
-0.2-0.2-0-0.3-0.5-0.5-0.7-0.6-0.4-0.8-0.7-1.1-1.2
Number Of Shares End
14.914.514.312.88.98.888.58.48.47.37.67.2
Net Income Continuing Discontinued Operations
-3-3-1.4-3.6-4-4.4-5.5-4.712.9-6.8-5.1-8.3-8.8
Normalized Income
-3-3-1.4-3.6-4-4.4-5.5-4.7-3.2-6.8-5.1-8.3-8.8
Interest Income
-------------
Interest
-------------
Net Interest Income
-------------
EBIT
-3-3-1.5-3.7-3.8-4.6-5.4-4.7-7.4-6-5.2-8.4-9
EBITDA
-2.4-2.4-0.9-3.2-3.4-4.4-5.4-4.7-7.3-6-5.2-8.4-9
Reconciled Cost Of Rev.
0.30.20.3-0---
Reconciled Depr.
0.60.60.50.50.50.20000000
Profit From Continuing Operations
-3-3-1.4-3.6-4-4.4-5.5-4.712.9-6.8-5.1-8.3-8.8
Normalized EBITDA
-2.4-2.4-0.9-3.2-3.4-4.4-5.4-4.7-27.7-6-5.2-8.4-9
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Dare Bioscience Inc competitor comparison and performance snapshot within industry

Dare Bioscience Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Dare Bioscience Inc Dec-2025 Annual Revenue is $1 Million which is growth of 10433.6% YoY.

  • NEGATIVE

    Annual Net Profit Dare Bioscience Inc Dec-2025 Annual Net Profit is $-13 Million which is growth of -230.6% YoY.

Dare Bioscience Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-53.6%
-
 102.8100.8
Cost Of Rev. Ann.
-
-
0.90.3----------
Gross Profit Ann.
-
-
0.50.7----------
Operating Exp. Ann.
-29.8%
-12.2%
11.614.323.533.841.439.127.414.311.73.737.937.2
Operating Profit Ann.
-
-
-11.1-13.6-23.5-30.9-31.4-39.1-27.4-14.3-11.7-3.7-37.2-37.2
⌄
-
-
 ---------0.3-2.2-2.4
Other Exp. Ann.
-20.6%
-
 0.219.40.80.40.40.1-5-7.5--
PBT Ann.
-
-
-11-13.4-4.1-30.2-31-38.7-27.4-14.3-16.7-11.5-39.3-39.6
Tax Ann.
-
-
 -----------
⌄
-
-
-11-13.4-4.1-30.2-31-38.7-27.4-15.1-16.7-11.5-39.3-39.6
Diluted NI Avail to Com Stockholders Ann.
-
-
-11-13.4-4.1-30.2-31-38.7-27.4-15.1-16.7-11.5-39.3-39.6
EPS Ann.
-
-
 -1.2-0.5-4.2-4.4-7.6-10.9-11.6-18.8-42.7-170.4-187.2
Diluted EPS Ann.
-
-
 -1.2-0.5-4.2-4.4-7.6-10.9-11.6-18.8-42.7-170.4-187.2
Number Of Shares End
28.1%
34.9%
 14.387.36.84.33.21.510.50.20.2
Total Exp. Ann.
-29.3%
-11.8%
 14.623.533.841.439.127.414.311.73.737.937.2
Net Income Continuing Discontinued Operations Ann.
-
-
-11-13.4-4.1-30.2-31-38.7-27.4-14.3-16.7-11.5-39.3-39.6
Normalized Income Ann.
-
-
-11-13.4-24.4-30.2-31-39.1-27.4-14.3-11.6-4-39.3-39.6
Interest Income Ann.
-
-
 ---------0.10
Interest Ann.
-
-
 --------0.32.22.4
EBITDA Ann.
-
-
-9-11.9-23.4-30.9-31.4-39-27.4-14.3-11.7-11.2-36.8-37
Reconciled Cost Of Rev. Ann.
-
-
0.90.3----------
Reconciled Depr. Ann.
-
-
2.11.6000000-0.30.2
Profit From Continuing Operations Ann.
-
-
-11-13.4-4.1-30.2-31-38.7-27.4-14.3-16.7-11.5-39.3-39.6
Normalized EBITDA Ann.
-
-
-9-11.9-43.8-30.9-31.4-39.4-27.4-14.3-6.5-3.7-36.8-37
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
2Y CAGR
-40.2%
3Y CAGR
-53.6%
Operating Exp. Ann.
1Y CHG
-39.1%
2Y CAGR
-35%
3Y CAGR
-29.8%
5Y CAGR
-12.2%
7Y CAGR
2.9%
10Y CAGR
-9.1%
Operating Expenses Annual Cr is falling faster than historical averages.

Dare Bioscience Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Dare Bioscience Inc Dec-2025 Total Shareholders Fund is $3 Million which is growth of 147.3% YoY.

  • POSITIVE

    Total Assets Dare Bioscience Inc Dec-2025 Total Assets is $32 Million which is growth of 46.9% YoY.

Dare Bioscience Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-9.5%
33.7%
32.522.121.343.855.87.67.47.814.337.778.2
⌄
-3.3%
27.7%
29.628.126.332.717.18.771.1124.629.5
⌄
-36.8%
-
2.8-6-5.111.138.8-1.20.46.713.313.148.7
Total Capitalization Ann.
-36.8%
-
2.8-6-5.111.138.8-1.20.46.713.317.661.4
Tangible Assets Ann.
-36.8%
-
2.8-6-5.111.138.8-1.20.46.78.113.148.7
Working Capital Ann.
-33.2%
-
3.4-3.2-2.911.439.2-0.70.86.27.419.961
Invested Capital Ann.
-36.8%
-
2.8-6-5.111.138.8-0.80.46.713.325.969.1
Tangible Book Value Ann.
-36.8%
-
2.8-6-5.111.138.8-1.20.46.78.113.148.7
Borrowings Ann.
75.4%
27.5%
2.71.31.40.50.30.80.8--12.820.3
Net Debt Ann.
-
-
-----------
Share Issued Ann.
26.9%
32.9%
14.58.78.37.173.51.610.50.20.2
Number Of Shares End
28.1%
34.9%
14.387.36.84.33.21.510.50.20.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
47.1%
2Y CAGR
23.5%
3Y CAGR
-9.5%
5Y CAGR
33.7%
7Y CAGR
22.6%
10Y CAGR
-8.4%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
9.7%
2Y CAGR
7.5%
3Y CAGR
-9.1%
5Y CAGR
25.2%
7Y CAGR
55.1%
10Y CAGR
3.8%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
3Y CAGR
-36.8%
7Y CAGR
-11.7%
10Y CAGR
-24.8%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Dare Bioscience Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Dare Bioscience Inc Book Value Per Share is $-0 which is growth of 97.0% YoY.

  • NEUTRAL

    ROE Dare Bioscience Inc ROE is 0% which is growth of 0% YoY.

Dare Bioscience Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--18.69%-92.65%-62.12%-122.15%-365.59%-197.16%-151.57%-44.29%-67.82%-60.16%
ROE Ann. %
-
-
---994.69%-124.12%-205.82%--420.05%-167.23%-87.13%-127.09%-84.18%
ROIC %
-
-
----82.8-26.8--212.1-35.8-51.1-15.7-14.1
OPM Ann. %
-
-
-1,315.52%-239,790.29%-1,101.89%-313.85%------4,850.39%-
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
-0.10.2-----0-
Working Capital Turnover Ann.
-30.7%
-
0.3-10.90
Quick Ratio Ann.
-
-
-0.70.61.23.30.716.38.12.24.7
Current Ratio Ann.
-
-
-0.90.91.43.40.91.26.68.62.24.7
Interest Coverage Ratio Ann.
-
-
---------34.7-16.6-15.3
LT Debt To Equity Ann.
-
-
---0--0.9--0.30.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Dare Bioscience Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Dare Bioscience Inc Dec-2025 Cash From Operating Activity is $-10 Million which is growth of -283.3% YoY.

  • POSITIVE

    Net Cash Flow Dare Bioscience Inc Dec-2025 Net Cash Flow is $9 Million which is growth of 71.4% YoY.

Dare Bioscience Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-9.95.4-38.9-18.1-28.8-25.2-13.3-10.3-2.5-33.5-31.9
⌄
-
-
-0.4-0.6-0.6-0.1-0-06.1-0.59.9-0.4-0.5
⌄
145.8%
-5.1%
19.30.415.61.375.925.15.210.10.2-757.1
Cash Plus Cash Eqv. End Of Year Ann.
-10.4%
39.7%
251610.834.751.74.74.86.87.63575.9
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
95.3-23.9-16.847.1-0.1-2-0.77.5-4124.7
Cash Plus Cash Eqv. Begin Of Year Ann.
-32.4%
27.2%
1610.834.751.74.74.86.87.6075.951.2
Income Tax Paid Supplemental Data Ann.
-
-
---------
Interest Paid Supplemental Data Ann.
-
-
---------1.31
Capex Ann.
-
-
-0.4-0.6-0.6-0.1-0-0--0--0.5-0.3
Issuance Of Capital Stock Ann.
159.2%
-1.9%
20.90.59.41.275.3235.210.1-0.939.8
Issuance Of Debt Ann.
-
4.6%
0.50.60.6-0.4-0.221
Repayment Of Debt Ann.
-
-
-1.8-0.6-0.3-------7.9-3.3
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-10.34.8-39.5-18.2-28.8-25.3-13.3-10.3-2.5-34.1-32.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
4725%
2Y CAGR
11.2%
3Y CAGR
145.8%
5Y CAGR
-5.1%
7Y CAGR
9.7%
10Y CAGR
-10.3%
Cash from Financing Annual Activity growth is higher than historical averages.
×